Viatris Welcomes FDA Date On Slow-Release Copaxone Product
Collaboration With Mapi Penned In 2018; Firm Plans Filing In Europe
Viatris and Mapi have moved a step closer to realizing the US launch of their 505(b)(2) once- monthly glatiramer acetate product, a follow-on to Teva’s Copaxone treatment for multiple sclerosis.
